ERBB2 and neoplasm: In this trial, patients with gastroesophageal cancer (n = 3,807) were centrally tested for HER2 status by IHC and FISH (patients were eligible if their tumor samples were scored as 3+ on IHC or if they were FISH positive (HER2:CEP17 ratio ≥ 2.0), and 22% were HER2 positive.